Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 8/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21182256 | 0.85 | BACE1 (0.41) | BACE1CNR2P4HTMCNR1CACNA1G | |
| SCHEMBL19672945 | 0.85 | HTT (0.41) | BACE1CNR2P4HTMALDH1A1CACNA1G | |
| SCHEMBL19992535 | 0.80 | BACE1 (0.39) | BACE1CNR2P4HTMCNR1CACNA1G | |
| SCHEMBL17992230 | 0.80 | BACE1 (0.38) | BACE1CNR2P4HTMCNR1CACNA1G | |
| SCHEMBL19992569 | 0.80 | BACE1 (0.42) | BACE1CNR2P4HTMALDH1A1CNR1 | |
| SCHEMBL1977314 | 0.78 | P4HTM (0.55) | BACE1P4HTMALDH1A1MAPTTSHR | |
| SCHEMBL15670153 | 0.78 | CYP1A2 (0.42) | BACE1CNR2ALDH1A1MAPTNPC1 | |
| SCHEMBL1976231 | 0.78 | MAPK1 (0.50) | BACE1CNR2P4HTMALDH1A1CNR1 | |
| SCHEMBL19992568 | 0.77 | BACE1 (0.37) | BACE1CNR2P4HTMCNR1CACNA1G | |
| SCHEMBL28883583 | 0.74 | ALDH1A1 (0.35) | P4HTMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514155-B1 | HETEROCYCLIC COMPOUND, AND HARMFUL-ARTHROPOD-CONTROLLING AGENT CONTAINING SAME | SUMITOMO CHEMICAL CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10721929-B2 | Heterocyclic compound and harmful-arthropod-controlling agent containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20190223436-A1 | HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING AGENT CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| EP-3514155-A1 | HETEROCYCLIC COMPOUND, AND HARMFUL-ARTHROPOD-CONTROLLING AGENT CONTAINING SAME | Sumitomo Chemical Company, Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018052119-A1 | HETEROCYCLIC COMPOUND, AND HARMFUL-ARTHROPOD-CONTROLLING AGENT CONTAINING SAME | 住友化学株式会社 | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190223436-A1 | HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING AGENT CONTAINING SAME | OXER1, TAAR1, NR1D1 | BACE1 3024/4885CNR2 64/4885P4HTM 2337/4885 |
| US-10721929-B2 | Heterocyclic compound and harmful-arthropod-controlling agent containing same | OXER1, TAAR1, NR1D1 | BACE1 3024/4885CNR2 64/4885P4HTM 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.